Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NCT07080385Phase 3Recruiting
- Sponsor
- Calcilytix Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1), sponsored by Calcilytix Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
encaleret
03
Conditions
autosomal dominant hypocalcemia type 1 (ADH1)
Beyond the preview
Go deeper on NCT07080385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080385.